We're rapidly approaching the end of 2012 and, while initial public offerings for tech companies usually grab the headlines, the health care space also had a number of exciting IPOs this year. Not all of them were winners, but Merrimack Pharmaceuticals (MACK +0.00%) is up more than 13% year to date (as of this writing). In the following video, health care analysts Max Macaluso and Brenton Flynn discuss Merrimack's business and drug pipeline.
Merrimack Pharmaceuticals is up since its IPO, but where will it go from here?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo